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Abstract
Background: The brown dog tick, Rhipicephalus sanguineus sensu lato, commonly infests dogs globally, is the major
vector of the pathogen that causes canine monocytic ehrlichiosis and also transmits Babesia vogeli. A rapid speed of kill
of a parasiticide is essential to reduce the direct deleterious effects of tick infestation and the risk of tick-borne pathogen
transmission. The speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner (Simparica™), against
R. sanguineus sensu lato on dogs was evaluated and compared with afoxolaner (NexGard®) for 5 weeks after a
single oral dose.
Methods: Based on pretreatment tick counts, 24 dogs were randomly allocated to oral treatment with either
placebo, or label doses of sarolaner (2–4 mg/kg) or afoxolaner (2.5–6.8 mg/kg). Dogs were examined and live
ticks counted at 8, 12, and 24 h after treatment and subsequent re-infestations on Days 7, 14, 21, 28, and 35.
Efficacy was determined at each time point relative to counts for placebo dogs.
Results: There were no adverse reactions to treatment. Based on geometric means, sarolaner provided >94 %
efficacy within 8 h of treatment, and >99 % after 12 and 24 h. Against subsequent weekly re-infestations of
ticks, sarolaner achieved ≥91.7 % efficacy (based on geometric means) to Day 35 at 24 h. Sarolaner significantly
reduced tick counts versus placebo on Days 0 and 28 at 8 h (P ≤ 0.0390), on Days 0 to 14 and 28 at 12 h (P ≤ 0.0142),
and on all days at 24 h (P < 0.0001). By comparison, tick counts for afoxolaner were significantly lower than placebo at
8 h on Days 0 and 28 (P ≤ 0.0117), at 12 h on Day 0 only (P < 0.0001), and on all days at 24 h (P ≤ 0.0078). Significantly
more live ticks were recovered from afoxolaner-treated dogs than from sarolaner-treated dogs at 8 and 12 h after
treatment (P ≤ 0.0286), at 12 h after re-infestation on Days 7 and 28 (P ≤ 0.04630), and at 24 h after re-infestations from
Day 7 to Day 35 (P ≤ 0.0119). At 24 h, efficacy (based on geometric mean counts) of afoxolaner was less than 90 %
from Day 7 onwards, and declined to less than 45 % by Day 35, while efficacy for sarolaner was >90 % for 35 days.
Conclusions: In this controlled laboratory evaluation, sarolaner had a faster speed of kill against R. sanguineus sensu
lato than afoxolaner. The rapid and consistent kill of ticks within 24 h after a single oral dose of sarolaner over 35 days
indicates that this treatment will provide highly effective and reliable control of ticks over the entire treatment interval
and should reduce the risk of tick-borne pathogen transmission.
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Background
The brown dog tick, Rhipicephalus sanguineus sensu
lato, is a pest of dogs world-wide [1]. Dogs are the pri-
mary host for this tick and all stages develop on the dog
though immature stages may also be found on other
small mammals [2]. The brown dog tick is unusual in
that it is commonly found indoors. Thus, its geographic
range is quite extensive as though R.sanguineus sensu
lato is generally considered to be a tropical tick and rela-
tively cold intolerant, it persists in temperate regions by
infesting kennels and homes [2]. Unfed larvae, nymphs
and adults can survive for many months off the host but
the life cycle can be completed in as little as 2–3
months. When dogs are constantly available as hosts,
tick populations can rapidly increase and infestations in
kennels or homes can be very difficult to control [3].
Rhipicephalus sanguineus sensu lato ticks are vectors
of a number of important pathogens globally [1]. The
major diseases transmitted by these ticks are canine
monocytic ehrlichiosis (caused by Ehrlichia canis) and
canine babesiosis (caused by Babesia vogeli) [4]. The
brown dog tick has been shown to harbor Anaplasma
platys and Babesia gibsoni [5, 6] and is a vector of a
number of Rickettsia pathogens [1] including the zoo-
nosis Rocky Mountain spotted fever, caused by Rickettsia
rickettsii [7] and may also be a vector of Cercopithifilaria
spp. and Hepatozoon canis [3].
Tick control and prevention on dogs is important to
prevent direct blood loss and irritation caused by the
feeding of ticks, and especially to reduce the risk of
pathogen transmission. Recently, a new class of systemic
compounds, the isoxazolines, have been introduced that
have efficacy against ticks and fleas for one month or
longer following a single oral dose [8, 9]. These system-
ically active compounds require the tick to bite in order
to kill the parasite. However, the compounds act rapidly
to impact the tick’s feeding behavior and cause death of
the ticks. One of these, afoxolaner, has been reported to
provide >90 % efficacy against R. sanguineus sensu lato
within 48 h for up to 28 days after a single dose [10, 11],
and efficacies of 86.4–99.5 % at 24 h for up to four
weeks after treatment [12]. Although product label effi-
cacy claims for ticks are typically based on evaluation at
48 h after treatment or re-infestation [13], the speed of
kill is critical in the prevention of feeding and reducing
the risk of pathogen transmission which generally re-
quires the tick to attach and feed for 24 to 48 h [14, 15],
though recently transmission of E. canis has been shown
to occur within as little as 3 h after attachment [16].
Sarolaner is a novel isoxazoline which, in a chewable
tablet formulation (Simparica™), provides excellent con-
trol of fleas and ticks for at least 1 month after a single
oral dose (TLMcTier, personal communications). A
laboratory study was conducted to determine and
compare the speed of kill of sarolaner and afoxolaner
(NexGard®) against existing R. sanguineus sensu lato in-
festations and weekly re-infestations on dogs for a
period of 5 weeks after treatment with a single dose.
Methods
Ethical approval
The study was a masked, negative controlled, random-
ized laboratory efficacy design conducted in California,
USA. Study procedures were in accordance with the
World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the effi-
cacy of parasiticides for the treatment, prevention, and
control of flea and tick infestation on dogs and cats [13]
and complied with the principles of Good Clinical Prac-
tices [17]. The protocol was reviewed and approved by
the local Institutional Animal Care and Use Committee.
Masking of the study was assured through the separ-
ation of functions. All personnel conducting observa-
tions or animal care or performing infestations and
counts were masked to treatment allocation.
Animals
Twenty-four, male and female, purpose-bred Beagles
ranging in age from 2.5 to 6.5 years and weighing 8.4 to
17.9 kg were used in the study. Each dog was individu-
ally identified by a unique ear tattoo and had undergone
an adequate wash-out period to ensure that no residual
ectoparasiticide efficacy remained from any previous treat-
ment as demonstrated by live tick retention at the host
suitability evaluation. Dogs were individually housed in
indoor runs such that no physical contact was possible
between dogs and they were acclimatized to these condi-
tions for at least 14 days prior to treatment. Dogs were fed
an appropriate maintenance ration of a commercial dry
canine feed for the duration of the study. Water was avail-
able ad libitum. All dogs were given a physical exam to
ensure that they were in good health at enrollment and
suitable for inclusion in the study. General health observa-
tions were performed twice daily throughout the study.
Design
The study followed a randomized complete block design.
Dogs were ranked according to decreasing tick counts
into blocks of three and within each block a dog was
randomly allocated to treatment with either sarolaner,
afoxolaner, or placebo. There were eight dogs per treat-
ment group. However, one afoxolaner-treated dog was
excluded from efficacy calculations as it was inadvert-
ently underdosed. Dogs were infested with ticks 2 days
prior to treatment and then weekly for 5weeks. Tick
counts were conducted at 8, 12, and 24 h after treatment
and after each subsequent weekly re-infestation.
Six et al. Parasites & Vectors  (2016) 9:91 Page 2 of 6
Treatment
Day -2 bodyweights were used to determine the appro-
priate dose to be administered. On Day 0, dogs received
either a placebo tablet, the appropriate strength sarola-
ner chewable tablet (Simparica™), to provide sarolaner at
the recommended minimum dose of 2 mg/kg (range 2
to 4 mg/kg), or NexGard® per label directions (afoxola-
ner at 2.5 to 6.8 mg/kg). All doses were administered by
hand pilling to ensure accurate and complete dosing.
Each dog was observed for several minutes after dos-
ing for evidence that the dose was swallowed, and also
for general health at 1, 4, and 24 h after treatment
administration.
Tick infestation and assessment
The ticks were obtained from a laboratory colony in
North Carolina which was initiated in 2008 with locally
collected ticks. Engorged females from various loca-
tions in the US are introduced annually. Tick infesta-
tions were performed on Days -7 (host suitability and
allocation), -2, 7, 14, 21, 28, and 35. Prior to each in-
festation, the dog was lightly sedated with ketamine/
xylazine and a precounted aliquot of 50 (±5) viable un-
fed adult R. sanguineus sensu lato were directly applied
to the animal. Each dog was examined to remove and
count live ticks at 48 h after the initial host suitability
infestation. At 8 and 12 (±1) hours after treatment and each
subsequent weekly re-infestation, the dogs were examined
and live ticks were counted in situ; the dogs were examined
systematically so that the entire body surface was carefully
examined once. At 24 h after treatment and each subse-
quent weekly re-infestation, the dogs were examined and
then thoroughly combed to count and remove live ticks.
Each dog was examined for at least 10 min. If ticks were
encountered in the last minute, combing was continued in
1 min increments until no ticks were encountered.
Statistical analysis
The individual dog was the experimental unit and the
primary end point was live tick counts. Data for post-
treatment live tick counts were summarized with arith-
metic (AM) and geometric (GM) means by treatment
group and time point. Tick counts were loge (count + 1)
transformed prior to analysis in order to stabilize the
variance and normalize the data. Using the PROC
MIXED procedure (SAS 9.2, Cary NC), transformed
counts were analyzed using a mixed linear model. The
fixed effects were treatment, time point and the inter-
action between time point and treatment by time point.
The random effects included block, block by treatment
interaction and error. Testing was two-sided at the sig-
nificance level α = 0.05.
The assessment of efficacy for live ticks was based on
the percent reduction in the arithmetic and geometric
mean live tick counts relative to placebo, as suggested by
the most recent guidelines of the WAAVP for systemic
acaricides [12] and was calculated using Abbott’s
formula:
% reduction ¼ 100  mean count placeboð Þ–mean count treatedð Þ
mean count placeboð Þ
Results
There were no treatment-related adverse events during
the study. Placebo-treated dogs maintained good tick in-
festations throughout the study with mean tick counts
ranging from approximately 25 to 37 (Tables 1, 2 and 3).
At the 8-hour time point, treatment with sarolaner
resulted in significantly lower GM tick counts than
placebo-treated dogs (P ≤ 0.0390) on Days 0 and 28,
and efficacy (GM) was 94.3 and 20.2 %, respectively
(Table 1). Treatment with afoxolaner resulted in sig-
nificantly lower tick counts than placebo at 8 h on
Days 0 and 28 as well (P ≤ 0.0117), with efficacy (GM)
of 71.2 and 13.7 %, respectively (Table 1). Sarolaner
had superior efficacy than afoxolaner at 8 h against the
existing infestation (P = 0.0238), but there were no sig-
nificant differences between the GM mean tick counts
at 8 h for sarolaner and afoxolaner-treated dogs on any
day for the subsequent post-treatment re-infestations
(P ≥ 0.0574).
At the 12-hour time point, sarolaner-treated dogs had
significantly lower tick counts than placebo-treated dogs
(P ≤ 0.0142) from treatment through Day 14 and on Day
28, with efficacy (GM) ranging from 29.2 to 99.5 %
(Table 2). Treatment with afoxolaner resulted in signifi-
cantly lower tick counts than placebo at 12 h on Day 0
only (P < 0.0001) with efficacy (GM) of 93.8 %. Efficacy
for afoxolaner was ≤14.6 % on all other days (Table 2).
Tick counts were significantly higher for afoxolaner-
treated dogs than for sarolaner-treated dogs on Days 0,
7, and 28 (P ≤ 0.0463).
At the 24-hour time point, both treatments resulted in
significantly lower tick counts than placebo-treated dogs
(P ≤ 0.0078) throughout the study, and sarolaner-treated
dogs also had significantly fewer ticks than afoxolaner-
treated dogs (P ≤ 0.0119) following all post-treatment re-
infestations (Days 7 to 35, Table 3). Treatment with
sarolaner resulted in efficacy (GM) of at least 91.7 %
through Day 35, while efficacy (GM) for dogs treated
with afoxolaner declined below 90 % from Day 7 on-
wards (Table 3, Fig. 1).
Discussion
A single dose of sarolaner resulted in the rapid reduc-
tion in R.sanguineus sensu lato ticks that had been
applied two days previously and in the rapid kill of re-
infestations for a full month after treatment. Efficacy
Six et al. Parasites & Vectors  (2016) 9:91 Page 3 of 6
Table 1 Mean live Rhipicephalus sanguineus sensu lato counts and efficacy relative to placebo at 8 hours after treatment and post-
treatment re-infestations for dogs treated with a single oral dose of either sarolaner or afoxolaner on Day 01
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 19–43 24–39 16–43 21–40 33–42 28–41
A. mean 32.1 34.1 32.3 32.9 36.5 33.4
G. mean2 31.2a 33.8a 31.1a 32.2a 36.4a 33.0a
Sarolaner Range 0–15 24–43 19–36 25–42 16–36 26–41
A. mean 3.5 32.3 27.4 31.0 29.8 32.3
Efficacy (%) 89.1 5.5 15.1 5.7 18.5 3.4
G. mean2 1.8b 31.8a 26.8a 30.6a 29.0b 31.9a
Efficacy (%) 94.3 5.8 13.7 5.1 20.2 3.2
P-value vs. placebo 0.0004 0.5773 0.2508 0.6717 0.0390 0.7036
Afoxolaner Range 3–27 26–48 25–39 26–41 29–34 28–37
A. mean 11.7 34.4 32.4 33.7 31.4 33.0
Efficacy (%) 63.5 0.0 0.0 0.0 13.9 1.1
G. mean2 9.0c 33.8a 32.2a 33.4a 31.4b 32.9a
Efficacy (%) 71.2 0.0 0.0 0.0 13.7 0.4
P-value vs. placebo 0.0070 0.9838 0.7788 0.7690 0.0117 0.9666
P-value vs. sarolaner 0.0238 0.5399 0.0574 0.3106 0.4449 0.6411
1n = 7 for afoxolaner, n = 8 for placebo and sarolaner groups
2Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Table 2 Mean live Rhipicephalus sanguineus sensu lato counts and efficacy relative to placebo at 12 hours after treatment and post-
treatment re-infestations for dogs treated with a single oral dose of either sarolaner or afoxolaner on Day 01
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 17–42 20–38 15–40 19–40 27–40 25–41
A. mean 28.6 30.5 30.9 31.9 34.4 32.1
G. mean2 27.5a 29.6a 29.8a 31.1a 34.2a 31.8a
Sarolaner Range 0–2 8–27 13–25 22–31 15–31 20–38
A. mean 0.3 20.0 19.8 24.9 24.6 27.3
Efficacy (%) 99.1 34.4 36.0 22.0 28.4 15.2
G. mean2 0.1b 18.9b 19.1b 24.7a 24.2b 26.7a
Efficacy (%) 99.5 36.1 35.9 20.5 29.2 15.9
P-value vs. placebo <0.0001 0.0142 0.0061 0.0754 0.0020 0.0715
Afoxolaner Range 0–5 26–42 16–34 23–36 25–33 23–35
A. mean 2.4 34.4 26.3 29.9 29.9 30.7
Efficacy (%) 91.5 0.0 14.9 6.3 13.1 4.4
G. mean2 1.7c 33.9a 25.5a,b 29.4a 29.7a 30.5a
Efficacy (%) 93.8 0.0 14.6 5.5 13.0 4.1
P-value vs. placebo <0.0001 0.3251 0.3213 0.6858 0.0553 0.6435
P-value vs. sarolaner 0.0286 0.0015 0.0732 0.0770 0.0463 0.1679
1n = 7 for afoxolaner, n = 8 for placebo and sarolaner groups
2Geometric means within columns with the same superscript are not significantly different (P > 0.05)
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of ≥91.7 % (based on GM) was achieved within 24 h for
35 days. This consistent efficacy at 24 h after treatment
and subsequent re-infestations for 35 days was signifi-
cantly superior to that of afoxolaner for all post-
treatment re-infestations. The decline in efficacy
against R. sanguineus sensu lato for afoxolaner from
89.4 % on Day 7 to 44.5 % by Day 35 after a single
treatment can be compared with published information.
Kunkle et al. [10] reported that a single oral dose of
afoxolaner resulted in efficacies (based on GM) against
R. sanguineus sensu lato of 98.5 % and 100 % at 48 h
after treatment and ranging from 98.1 to 99.4 % for
subsequent weekly re-infestations to Day 35, but did
not assess efficacy at earlier time points. Another study
evaluated the efficacy of afoxolaner at 24 h time points
[12], but the first evaluation (AM efficacy of 99.5 %)
Table 3 Mean live Rhipicephalus sanguineus sensu lato counts and efficacy relative to placebo at 24 hours after treatment and post-
treatment re-infestations for dogs treated with a single oral dose of either sarolaner or afoxolaner on Day 01
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 19–43 17–41 11–34 20–39 24–38 19–37
A. mean 28.8 30.5 26.9 30.0 31.5 28.0
G. mean2 27.8a 29.5a 25.6a 29.2a 31.2a 27.3a
Sarolaner Range 0–1 0–2 0–3 0–1 0–6 0–11
A. mean 0.1 0.6 1.5 0.3 1.3 3.4
Efficacy (%) 99.6 98.0 94.4 99.2 96.0 87.9
G. mean2 0.1b 0.5b 1.1b 0.2b 0.7b 2.3b
Efficacy (%) 99.7 98.3 95.7 99.4 97.8 91.7
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0001
Afoxolaner Range 0–0 0–11 2–16 0–15 1–22 11–31
A. mean 0.0 4.1 7.6 8.7 9.6 16.0
Efficacy (%) 100.0 86.4 71.8 71.0 69.6 42.9
G. mean2 0.0b 3.1c 6.2c 6.2c 7.3c 15.2c
Efficacy (%) 100 89.4 76.0 78.8 76.5 44.5
P-value vs. placebo <0.0001 0.0002 0.0006 0.0078 0.0041 0.0021
P-value vs. sarolaner 0.3833 0.0119 0.0028 0.0022 0.0022 0.0008
1n = 7 for afoxolaner, n = 8 for placebo and sarolaner groups
2Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 8, 12, and 24 hours after treatment and post-treatment re-infestations
of Rhipicephalus sanguineus sensu lato for dogs treated with a single oral dose of either sarolaner or afoxolaner on Day 0
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was not conducted until after the second treatment
when ticks were applied immediately after the dogs
were dosed; efficacy (AM) of afoxolaner at 24 h for
ticks re-infested 21 days after the second treatment was
93.7 %, and at 28 days after the third monthly treat-
ment efficacy (AM) was 86.4 %. As some cumulative ef-
fect of repeat dosing at 28 day intervals would be
expected, these published data are in good agreement
with the 24 h efficacy seen in the current study follow-
ing a single dose (e.g. AM efficacy for afoxolaner of
71.0 and 69.6 % on Days 21 and 28, respectively after a
single dose). The 24 h AM efficacy for sarolaner on
these two days was 99.2 and 96.0 %, respectively.
The rapid kill of ticks is critical to reduce the risk of
tick-borne pathogen transmission and to alleviate the
irritation and blood loss that is a direct consequence of
tick feeding. Thus, the speed of kill of sarolaner against
R. sanguineus sensu lato and its consistent high efficacy
over the full month following a single oral dose should
provide a marked reduction in the discomfort caused
by tick infestation and also reduce the risk of a treated
dog becoming infected with the pathogens transmitted
by R. sanguineus sensu lato.
Conclusions
This study confirmed the excellent acaricidal efficacy of
sarolaner against R. sanguineus sensu lato after a single
oral administration, and demonstrated that ticks were
killed rapidly with the vast majority controlled within 24
h for 35 days. Efficacy for sarolaner was higher than that
of afoxolaner at 8 and 12 h after treatment, and consist-
ently superior against re-infestations from Day 7 on-
wards at 24 h. Thus, sarolaner (Simparica™) offers the
pet owner and veterinarian a highly effective oral prod-
uct with a rapid speed of kill against ticks for the entire
month following a single oral dose. It provides a new op-
tion for the treatment and prevention of tick infestation
that should also reduce the risk of tick-borne pathogen
transmission.
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